Refine by
Tumor Samples Articles & Analysis
19 news found
Massimo Cristofanilli, a Professor of Medicine at Weill Cornell Medicine, and at Tethis, will focus on patients with early-stage breast cancer who are given drugs to reduce tumor size, prior to surgery to remove the tumors. Blood samples will be collected at key points: diagnosis, post-treatment initiation, and multiple times after surgery. As ...
Ilkka Haapala’s PhD dissertation explored the possibility of differentiating tumour types and specific mutations based on DMS. We want to congratulate Ilkka on his successful defense of the dissertation at Tampere University on 11.10.2024! IonVision was used as the DMS in several of the studies. The dissertation found that DMS can be used to identify the most common brain tumour ...
Rarecells leverages its proprietary ISET® Circulating Tumor Cells (CTC) platform, combined with cutting-edge downstream analyses, to generate a novel and powerful approach to detect evidence of a tumor from a blood sample. ...
Retrospective tumor samples and corresponding clinical response data were collected from patients with a primary diagnosis of RCC who were treated with high-dose IL-2 (HD-IL-2; aldesleukin) and compared to existing data from a similar cohort of RCC patients treated with the anti-PD-1 nivolumab2. Tumor samples from HD-IL-2 treated ...
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. The Series A2 round was led by the Washington Research Foundation along with ...
THE OFFER WILL COME IN COMBINATION WITH ONCODNA’S DATA ANALYSIS AND CLINICAL INTERPRETATION TOOLS FOR THE RAPID ANALYSIS AND REPORTING OF A PATIENT’S TUMOR MOLECULAR PROFILE. ONCODEEP KIT IS AVAILABLE FOR EARLY ACCESS AND WILL BE COMMERCIALLY AVAILABLE BY THE END OF Q2 2022. ...
GRIDSS Somatic Filter filters somatic calls from a VCF generated by GRIDSS joint tumor/normal variant calling. GRIDSS VIRUSBreakend is a high-speed viral integration detection tool. ...
” In this retrospective study of real-world data, clinical response data and existing tumor samples were collected from about 250 patients with non-squamous non-small cell lung cancer (NSCLC) who were treated with either pemetrexed/platinum doublet chemotherapy, pembrolizumab (Keytruda®), or the combination of the two. ...
This workflow takes a pair of matched tumor/normal BAM files and produces allele-specific copy number of every base of the genome, overall sample purity and ploidy, annotated SV clusters and gene fusion predictions. Moreover, it outputs detailed visualisations of the rearrangements in the tumor genome via integrated Circos plots showing copy ...
The use of proteomics can comprehensively, dynamically and quantitatively analyze the changes of protein types and quantities in normal and cancerous specimens, which not only can help to elucidate the pathogenesis of tumors but can also screen and identify tumor-specific markers and specific antigens. ...
“TK-8001 is a novel CD8 TCR-T targeting MAGE-A1, a tumor-specific antigen associated with aggressive cancers and poor clinical prognosis,” stated Eugen Leo, Chief Medical Officer of T-knife. “The presentations at SITC will cover important aspects of our work related with TK-8001, including favorable preclinical data comparing TK-8001 to human donor-derived TCRs, ...
RNA sequencing was performed on tumor samples obtained from these patients at initial diagnosis, prior to any systemic treatment. 30 patients (0.9% of all patients and 1.1% of all patients with ER-positive tumors) were found to have an ESR1 mutation already present in their tumor. ...
In an ovarian cancer cohort of 44 evaluable patient samples, authors found that: Ovarian cancer patient-derived 3D cultures preserve the histopathological and molecular features of original tumor samples. For 82% of patient samples tested, the PARIS® Test identified at least one drug with good to exceptional response that ...
In cases where comprehensive molecular profiling cannot be performed, such as when tumor sample is insufficient, oncologists and pathologists may pivot to broad molecular profiling, coverage for which the Ministry of Health approved in April for tests that assess up to 100 genes. Six laboratories are already approved to perform broad molecular profiling using the ...
Collection of fresh-frozen tumor samples is often challenging or infeasible, leading many studies to rely on formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. ...
Specifically, the test would be used with patients whose tumors harbor a rearranged during transfection (RET) alteration. RET variants are found in about two percent of NSCLC, about 60 percent of medullary thyroid cancer (MTC) and up to approximately 20 percent of other thyroid cancers. ...
The research team examined TCR convergence in a set of 85 melanoma tumor biopsies and discovered that convergent TCRs were abundant within tumor, but not in the peripheral blood of healthy donors. ...
Both products will enable researchers to rapidly and accurately identify disease-associated variants in tumor samples-information that can be vital to research in cancer treatments. ...
This panel provides comprehensive coverage of mutations and enables swift progression of sample processing in less than a day. The AML gene panel will be followed in the coming months by the release of additional research panels for lung, lymphoma and colorectal cancer and a comprehensive cancer panel. ...